Abstract
Fungal infections are very common in immunocompromissed patients and the morbid and mortality are frequently increasing. The number of drugs available for the treatment of fungal infections is very limited demanding the development of new drugs. Brazilian biodiversity is wide and poorly explored representing important source of new molecules to chemistry and pharmaceutics companies. Regar…